The limitations of persistence as a measure of efficacy of biologic therapies
Author:
Affiliation:
1. Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA , USA
Publisher
Oxford University Press (OUP)
Subject
Dermatology
Link
https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljad322/52137857/ljad322.pdf
Reference6 articles.
1. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS);Marcombes;Br J Dermatol,2023
2. First-line persistence of biologics in psoriasis from a cohort based on French medico-administrative data;Marcombes;J Invest Dermatol,2023
3. Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French health insurance database;Pina Vegas;JAMA Dermatol,2022
4. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM);Sbidian;Br J Dermatol,2019
5. Persistence of treatment with conventional systemic agents for patients with psoriasis: a real-world analysis of 73 168 new users from the French National Health Insurance database;Bergqvist;Br J Dermatol,2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3